Comparing the Expression Profiles of Steroid Hormone Receptors and Stromal Cell Markers in Prostate Cancer at Different Gleason Scores

Overview

Journal Sci Rep

Specialty Science

Date 2018 Sep 27

PMID 30254333

Citations 3

Authors

Thomas Gevaert

Yves-Remi Van Eycke

Thomas Vanden Broeck

Hein van Poppel

Isabelle Salmon

Sandrine Rorive

Frank Claessens

Dirk De Ridder

Christine Decaestecker

Steven Joniau

Affiliations

Soon will be listed here.

Abstract

The recent developments in anti-angiogenic and immunomodulatory drugs show that the tumour micro-environment (TME) becomes increasingly important in cancer research. Here we investigated the correlation between the Gleason score (GS) and the TME by comparing tissue expression profiles of steroid hormone receptors, cancer activated fibroblast (CAF) markers and vessel densities between different GS groups. Therefore, matched patient cohorts were composed for different GS (6-7-8). Tissue micro-arrays with 6 samples/patient were processed for immunohistochemistry. Stained slides were digitised, stroma and epithelium were selectively annotated, and all selected areas were quantitatively analysed for marker expression. The most striking findings were decreased stromal expression levels of several steroid hormone receptors, increased CAF-phenotypes and increased vessel densities in high GS prostate cancer compared to low GS prostate cancer and paired prostate non-tumour tissue. The present data reveal a complex correlation between prostate cancer differentiation and TME components and suggest that different GS can be associated with different possible actionable targets in the TME. The use of standardised digital image analysis tools generated robust and reproducible quantitative data, which is novel and more informative compared to the classic semi-quantitative and observer-dependent visual scoring of immunohistochemistry.

Citing Articles

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Narayan V, Barber-Rotenberg J, Jung I, Lacey S, Rech A, Davis M Nat Med. 2022; 28(4):724-734.

PMID: 35314843 PMC: 10308799. DOI: 10.1038/s41591-022-01726-1.

Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.

Linares J, Marin-Jimenez J, Badia-Ramentol J, Calon A Front Cell Dev Biol. 2021; 8:621070.

PMID: 33553157 PMC: 7862334. DOI: 10.3389/fcell.2020.621070.

The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.

Gevaert T, Van Eycke Y, Vanden Broeck T, van Poppel H, Salmon I, Rorive S PLoS One. 2020; 15(12):e0244663.

PMID: 33370412 PMC: 7769484. DOI: 10.1371/journal.pone.0244663.

References

Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B . Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun. 2017; 8:15840. PMC: 5501969. DOI: 10.1038/ncomms15840. View

Shaw G, Whitaker H, Corcoran M, Dunning M, Luxton H, Kay J . The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. Eur Urol. 2015; 70(2):214-8. PMC: 4926724. DOI: 10.1016/j.eururo.2015.10.042. View

Yu Y, Yang O, Fazli L, Rennie P, Gleave M, Dong X . Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate. 2015; 75(10):1043-50. DOI: 10.1002/pros.22988. View

Van Eycke Y, Allard J, Salmon I, Debeir O, Decaestecker C . Image processing in digital pathology: an opportunity to solve inter-batch variability of immunohistochemical staining. Sci Rep. 2017; 7:42964. PMC: 5318955. DOI: 10.1038/srep42964. View

Tennill T, Gross M, Frieboes H . Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017; 12(5):e0178362. PMC: 5446169. DOI: 10.1371/journal.pone.0178362. View

Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P . Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int. 2015; 118(2):243-9. DOI: 10.1111/bju.13224. View

Sirinukunwattana K, Pluim J, Chen H, Qi X, Heng P, Guo Y . Gland segmentation in colon histology images: The glas challenge contest. Med Image Anal. 2016; 35:489-502. DOI: 10.1016/j.media.2016.08.008. View

Shiao S, Chu G, Chung L . Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett. 2016; 380(1):340-8. PMC: 5317350. DOI: 10.1016/j.canlet.2015.12.022. View

Kassouf W, Ismail H, Aprikian A, Chevalier S . Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis. 2004; 7(2):105-10. DOI: 10.1038/sj.pcan.4500716. View

10.

Di Vizio D, Morello M, Sotgia F, Pestell R, Freeman M, Lisanti M . An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009; 8(15):2420-4. PMC: 2927821. DOI: 10.4161/cc.8.15.9116. View

11.

Gevaert T, Lerut E, Joniau S, Franken J, Roskams T, Ridder D . Characterization of subepithelial interstitial cells in normal and pathological human prostate. Histopathology. 2014; 65(3):418-28. DOI: 10.1111/his.12402. View

12.

Samaratunga H, Delahunt B, Yaxley J, Srigley J, Egevad L . From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scand J Urol. 2016; 50(5):325-9. DOI: 10.1080/21681805.2016.1201858. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Leach D, Need E, Toivanen R, Trotta A, Palethorpe H, Palenthorpe H . Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget. 2015; 6(18):16135-50. PMC: 4599261. DOI: 10.18632/oncotarget.3873. View

15.

El-Gohary Y, Silverman J, Olson P, Liu Y, Cohen J, Miller R . Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol. 2007; 127(4):572-9. DOI: 10.1309/X6NXYE57DLUE2NQ8. View

16.

Karam J, Lotan Y, Roehrborn C, Ashfaq R, Karakiewicz P, Shariat S . Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007; 67(6):614-22. DOI: 10.1002/pros.20557. View

17.

San Martin R, Barron D, Tuxhorn J, Ressler S, Hayward S, Shen X . Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. Am J Pathol. 2014; 184(6):1860-70. PMC: 4044710. DOI: 10.1016/j.ajpath.2014.02.021. View

18.

Hetzl A, Montico F, Lorencini R, Kido L, Candido E, Billis A . Fibroblast growth factor, estrogen, and prolactin receptor features in different grades of prostatic adenocarcinoma in elderly men. Microsc Res Tech. 2013; 76(3):321-30. DOI: 10.1002/jemt.22170. View

19.

Bonkhoff H . Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. Prostate. 2017; 78(1):2-10. DOI: 10.1002/pros.23446. View

20.

Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D . Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8(9):2912-23. View